+91 80 2808 2808
Biocon  /  Products  /  Auto-immune Diseases


Autoimmune diseases are becoming a global health problem and can be chronic and life-threatening. Statistics show that around 50 Mn in the U.S. itself suffer from autoimmune diseases.

This makes it all the more imperative to fast track their cure. Biocon is pioneering targeted therapies and exploring potential treatments to transform the breakdown of the body’s immunity into a breakthrough medical innovation


Biocon is one of the world’s largest producers of Immunosuppressants

As one of the world’s largest producers of immunosuppressants, Biocon leverages its comprehensive portfolio of topical, systemic and biologic therapies to treat immune-mediated skin diseases like psoriasis, atopic dermatitis and vitiligo.

Biocon’s Itolizumab (Mab)

the world’s first novel and differentiated anti-CD6 monoclonal antibody

Itolizumab is the first biological drug for chronic plaque psoriasis, specially researched, developed and manufactured in India.

  • Launched as ALZUMAb™ in India
  • An approved ‘first-in-class’ therapy
  • Binds to a specific molecule (CD6) on the surface of T cells to block their autoimmune activation, thereby preventing the formation of plaques
  • An affordable biologic therapy with a less aggressive dosing regimen and a longer treatment free period
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>